These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 647986)

  • 1. Technetium uptake in the management of thyrotoxicosis.
    Van't Hoff W; Pover GG; Drury PL
    Clin Endocrinol (Oxf); 1978 Apr; 8(4):327-33. PubMed ID: 647986
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of 99 Tc m for the routine assessment of thyroid function.
    Goolden AW; Glass HI; Williams ED
    Br Med J; 1971 Nov; 4(5784):396-9. PubMed ID: 5124438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iodine organification defect following treatment of thyrotoxicosis with antithyroid drugs.
    Horton PW; Millar WT; McLarty DG; Alexander WD
    Clin Endocrinol (Oxf); 1975 Jul; 4(4):357-62. PubMed ID: 168992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The behaviour of the thyroidal iodide trap after subtotal thyroidectomy for thyrotoxicosis and its implication for the T3-suppression test.
    Wilkin TJ; Gunn A; Isles TE; Crooks J; Beck JS
    Acta Endocrinol (Copenh); 1979 Sep; 92(1):85-94. PubMed ID: 494988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The diagnostic and prognostic value of the 20 min 99mTc-uptake in the thyroid gland.
    Kirkegaard C; Friis T; Molholm Hansen JE; Siersbaek-Nielsen K
    Acta Endocrinol (Copenh); 1973 Dec; 74(4):659-65. PubMed ID: 4800903
    [No Abstract]   [Full Text] [Related]  

  • 6. Thyroid suppressibility: follow-up for two years after antithyroid treatment.
    Lowry RC; Lowe D; Hadden DR; Montgomery DA; Weaver JA
    Br Med J; 1971 Apr; 2(5752):19-22. PubMed ID: 4101408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The variation in serum triiodothyronine (T3) achieved during suppression testing in thyrotoxicosis.
    Wilkin TJ; Isles TE; Newton RW; Gunn A; Crooks J; Beck JS
    Clin Endocrinol (Oxf); 1978 Dec; 9(6):549-55. PubMed ID: 747896
    [No Abstract]   [Full Text] [Related]  

  • 8. Relapse of Graves' disease after medical therapy: predictive value of thyroidal technetium-99m uptake and serum thyroid stimulating hormone receptor antibody levels.
    Wilson R; McKillop JH; Pearson DW; Cuthbert GF; Thomson JA
    J Nucl Med; 1985 Sep; 26(9):1024-8. PubMed ID: 2863338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Studies of thyroid function using 99Tcm in thyrotoxic patients during treatment with antithyroid drugs.
    Goolden AW; Williams ED; Thalassinos NC
    Clin Endocrinol (Oxf); 1973 Jan; 2(1):65-73. PubMed ID: 4770264
    [No Abstract]   [Full Text] [Related]  

  • 10. Thyroid function in patients in clinical remission after medical treatment of thyrotoxicosis.
    Hooper MJ; Ratcliffe JG; Ratcliffe WA; Spencer CA; McLarty DG; Alexander WD
    J Clin Endocrinol Metab; 1975 May; 40(5):807-11. PubMed ID: 47864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of the long-term results of antithyroid drug therapy for thyrotoxicosis.
    Alexander WD; McLarty DG; Robertson J; Shimmins J; Brownlie BE; Harden RM; Patel AR
    J Clin Endocrinol Metab; 1970 Apr; 30(4):540-3. PubMed ID: 4190916
    [No Abstract]   [Full Text] [Related]  

  • 12. Apathetic T-3 toxicosis.
    Fairclough PD; Besser GM
    Br Med J; 1974 Mar; 1(5904):364-5. PubMed ID: 4819175
    [No Abstract]   [Full Text] [Related]  

  • 13. Dissociation of responsiveness to thyrotropin-releasing hormone and thyroid suppressibility following antithyroid drug therapy of hyperthyroidism.
    Martino E; Pinchera A; Capiferri R; Macchia E; Sardano G; Bartalena L; Mazzanti F; Baschieri L
    J Clin Endocrinol Metab; 1976 Sep; 43(3):543-9. PubMed ID: 821960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Technetium-99 m in the diagnosis of thyrotoxicosis.
    Hoff W van't ; Pover GG; Eiser NM
    Br Med J; 1972 Oct; 4(5834):203-6. PubMed ID: 4117169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroidal suppressibility after stopping long-term treatment of thyrotoxicosis with anti-thyroid drugs.
    Alexander WD; Harden RM; McLarty D; Shimmins J
    Metabolism; 1969 Jan; 18(1):58-62. PubMed ID: 4179400
    [No Abstract]   [Full Text] [Related]  

  • 16. Unexpected differences in early thyroidal trapping of iodide and pertechnetate.
    Hilditch TE; Alexander WD
    Eur J Nucl Med; 1980 Apr; 5(2):115-7. PubMed ID: 6155269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of preoperative drug treatment on the histological appearances and in vitro 131I uptake of human hyperplastic thyroid gland.
    Beck JS; Elmslie WH; Harbitz TB; Michie W; Nicol AG; Pegg CA; Young RJ
    Clin Endocrinol (Oxf); 1975 Sep; 4(5):469-75. PubMed ID: 1175309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Four-year follow-up of thyrotoxic patients treated with antithyroid drugs bases on thyroid suppressibility-Prognostic value of the 20-min 131-I thyroid uptake (author's transl)].
    Leclere J; Ueda M; Hartemann P; Maureira JJ; Mizrahi R; Zannetti A; Weyland M; Vaillant D
    Ann Endocrinol (Paris); 1980; 41(2):95-105. PubMed ID: 6162414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prediction of the long-term results of antithyroid drug therapy for thyrotoxicosis.
    Hales I; Stiel J; Reeve T; Heap T; Myhill J
    J Clin Endocrinol Metab; 1969 Jul; 29(7):998-1001. PubMed ID: 4183236
    [No Abstract]   [Full Text] [Related]  

  • 20. Propranolol versus carbimazole as the sole treatment for thyrotoxicosis. A consideration of circulating thyroid hormone levels and tissue thyroid function.
    O'Malley BP; Abbott RJ; Barnett DB; Northover BJ; Rosenthal FD
    Clin Endocrinol (Oxf); 1982 Jun; 16(6):545-52. PubMed ID: 7105427
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.